Local immunotherapy (β-IFN) and systemic chemotherapy in primary glial tumors

A. Boiardi, A. Silvani, I. Milanesi, L. Munari, G. Broggi, M. Botturi

Research output: Contribution to journalArticlepeer-review


Dosage and schedules for the treatment of malignant glial tumors using IFN (interferon) are still uncertain and controversial. In this study we give the preliminary results of treatment in 28 patients with glioblastoma multiforme (GBM). 6 patients were treated with local injection of β-IFN through an Ommaya reservoir; 4 patients with β-IFN followed by systemic chemotherapy (Cisplatin+Etoposide), and 18 patients with chemotherapy only. Two end points were evaluated: 1) Whether or not the patients responded to treatment. 2) Length of Time to Tumor Progression(TTP) after surgery. We found that IFN alone was ineffective. Results were improved when local immunotherapy was associated with systemic chemotherapy. New drugs and investigation of possible pharmacological synergism are needed.

Original languageEnglish
Pages (from-to)163-168
Number of pages6
JournalItalian Journal of Neurological Sciences
Issue number2
Publication statusPublished - Apr 1991


  • chemotherapy
  • glial tumor
  • Interferon

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'Local immunotherapy (β-IFN) and systemic chemotherapy in primary glial tumors'. Together they form a unique fingerprint.

Cite this